{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:56:40Z","timestamp":1786982200690,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Collaborative Academic Innovation Project of Shandong cancer hospital","award":["TS006"],"award-info":[{"award-number":["TS006"]}]},{"name":"the National Scientific Foundation","award":["No.8217207"],"award-info":[{"award-number":["No.8217207"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01478-y","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T14:51:31Z","timestamp":1778338291000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Microwave Ablation with or without TACE for Unresectable Large Hepatocellular Carcinoma: Impact of Tumor Burden Score on Efficacy"],"prefix":"10.1007","volume":"57","author":[{"given":"Zhen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"6","key":"1478_CR1","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"RumgayH, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598\u2013606. IF: 33.0 Q1 B1 https:\/\/doi.org\/10.1016\/j.jhep.2022.08.021","journal-title":"J Hepatol"},{"issue":"6","key":"1478_CR2","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.jhep.2022.08.021","volume":"32","author":"A Vogel","year":"2021","unstructured":"VogelA, Martinelli E, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org; ESMO Guidelines Committee. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol. 2021;32(6):801\u20135. IF: 33.0 Q1 B1 https:\/\/doi.org\/10.1016\/j.jhep.2022.08.021","journal-title":"Ann Oncol"},{"issue":"3","key":"1478_CR3","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681\u201393. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018","journal-title":"J Hepatol"},{"key":"1478_CR4","unstructured":"NCCN Clinical Practice Guidelines in Oncology- Hepatocellular Carcinoma. (2024 Version 1). https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1514"},{"key":"1478_CR5","doi-asserted-by":"publisher","unstructured":"Cheng PL, Wu PH, Kao WY et al. Comparison of local ablative therapies, including radiofrequency ablation, microwave ablation, stereotactic ablative radiotherapy, and particle radiotherapy, for inoperable hepatocellular carcinoma: a systematic review and meta-analysis. Exp Hematol Oncol. 2023. https:\/\/doi.org\/10.1186\/s40164-023-00400-7","DOI":"10.1186\/s40164-023-00400-7"},{"key":"1478_CR6","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1136\/gutjnl-2016-312629","volume":"66","author":"J Yu","year":"2017","unstructured":"Yu J, Yu X, Han Z, et al. Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial. Gut. 2017;66:1172\u20133. https:\/\/doi.org\/10.1136\/gutjnl-2016-312629","journal-title":"Gut"},{"key":"1478_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S2468-1253(18)30029-3","volume":"3","author":"N Vietti Violi","year":"2018","unstructured":"Vietti Violi N, Duran R, Guiu B, et al. Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2018;3:317\u201325. https:\/\/pubmed.ncbi.nlm.nih.gov\/29503247\/","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"1478_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000502479","volume":"9","author":"K Kariyama","year":"2020","unstructured":"Kariyama K, Nouso K, Wakuta A, et al. Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies [J]. Liver Cancer. 2020;9(1):41\u20139. https:\/\/doi.org\/10.1159\/000502479","journal-title":"Liver Cancer"},{"key":"1478_CR9","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.2147\/JHC.S424009","volume":"10","author":"J Yang","year":"2023","unstructured":"Yang J, Liang S, Liu H, et al. Efficacy and Safety of Microwave Ablation Assisted by Ultrasound Fusion Imaging for Primary and Secondary Liver Cancers with a Diameter of 3\u20137 Cm [J]. J Hepatocell Carcinoma. 2023;10:1839\u201348. https:\/\/doi.org\/10.2147\/JHC.S424009","journal-title":"J Hepatocell Carcinoma"},{"issue":"1","key":"1478_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/02656736.2019.1711203","volume":"37","author":"C An","year":"2020","unstructured":"An C, Cheng Z, Yu X, et al. Ultrasound-guided percutaneous microwave ablation of hepatocellular carcinoma in challenging locations: oncologic outcomes and advanced assistive technology. Int J Hyperth. 2020;37(1):89\u2013100. https:\/\/doi.org\/10.1080\/02656736.2019.1711203","journal-title":"Int J Hyperth"},{"issue":"6","key":"1478_CR11","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1159\/000517393","volume":"10","author":"YW Hung","year":"2021","unstructured":"Hung YW, Lee IC, Chi CT, et al. Redefining Tumor Burden in Patients with Intermediate-Stage Hepatocellular Carcinoma: The Seven-Eleven Criteria. Liver Cancer. 2021;10(6):629\u201340. https:\/\/doi.org\/10.1159\/000517393","journal-title":"Liver Cancer"},{"issue":"4","key":"1478_CR12","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/SLA.0000000000004346","volume":"272","author":"DI Tsilimigras","year":"2020","unstructured":"Tsilimigras DI, Mehta R, Paredes AZ, et al. Overall Tumor Burden Dictates Outcomes for Patients Undergoing Resection of Multinodular Hepatocellular Carcinoma Beyond the Milan Criteria. Ann Surg. 2020;272(4):574\u201381. https:\/\/doi.org\/10.1097\/SLA.0000000000004346","journal-title":"Ann Surg"},{"issue":"7","key":"1478_CR13","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/bjs.11464","volume":"107","author":"DI Tsilimigras","year":"2020","unstructured":"Tsilimigras DI, Moris D, Hyer JM, et al. Hepatocellular carcinoma tumor burden score to stratify prognosis after resection. Br J Surg. 2020;107(7):854\u201364. https:\/\/doi.org\/10.1002\/bjs.11464","journal-title":"Br J Surg"},{"issue":"9","key":"1478_CR14","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1080\/17474124.2022.2117156","volume":"16","author":"SY Ho","year":"2022","unstructured":"Ho SY, Liu PH, Hsu CY, et al. Tumor burden score as a new prognostic surrogate in patients with hepatocellular carcinoma undergoing radiofrequency ablation: role of albumin-bilirubin (ALBI) grade vs easy ALBI grade. Expert Rev Gastroenterol Hepatol. 2022;16(9):903\u201311. https:\/\/doi.org\/10.1080\/17474124.2022.2117156","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1478_CR15","doi-asserted-by":"publisher","first-page":"1330851","DOI":"10.3389\/fonc.2024.1330851","volume":"14","author":"Z Wei","year":"2024","unstructured":"Wei Z, Xie K, Xu F, Dai C. The tumor burden score may be a discriminator in microwave ablation versus liver resection for hepatocellular carcinoma within the Milan criteria: a propensity score matching and inverse probability of treatment weighting study. Front Oncol. 2024;14:1330851. . Published 2024 Feb 16. https:\/\/doi.org\/10.3389\/fonc.2024.1330851","journal-title":"Front Oncol"},{"issue":"2","key":"1478_CR16","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jamacardio.2022.4466","volume":"8","author":"NA Marston","year":"2023","unstructured":"Marston NA, Pirruccello JP, Melloni GEM, et al. Predictive Utility of a Coronary Artery Disease Polygenic Risk Score in Primary Prevention. JAMA Cardiol. 2023;8(2):130\u20137. https:\/\/doi.org\/10.1001\/jamacardio.2022.4466.","journal-title":"JAMA Cardiol"},{"issue":"6","key":"1478_CR17","doi-asserted-by":"publisher","first-page":"575","DOI":"10.5152\/dir.2020.19615","volume":"26","author":"C Liu","year":"2020","unstructured":"Liu C, Li T, He JT, Shao H. TACE combined with microwave ablation therapy vs. TACE alone for the treatment of early- and intermediate-stage hepatocellular carcinomas larger than 5\u00a0cm: a meta-analysis. Diagn Interv Radiol. 2020;26(6):575\u201383. https:\/\/doi.org\/10.5152\/dir.2020.19615.","journal-title":"Diagn Interv Radiol"},{"issue":"9","key":"1478_CR18","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1007\/s00261-018-1464-9","volume":"43","author":"AR Smolock","year":"2018","unstructured":"Smolock AR, Cristescu MM, Hinshaw A, et al. Combination transarterial chemoembolization and microwave ablation improve local tumor control for 3- to 5-cm hepatocellular carcinoma when compared with transarterial chemoembolization alone. Abdom Radiol (NY). 2018;43(9):2497\u2013504. https:\/\/doi.org\/10.1007\/s00261-018-1464-9.","journal-title":"Abdom Radiol (NY)"},{"issue":"5","key":"1478_CR19","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.4103\/jcrt.JCRT_380_19","volume":"16","author":"X Li","year":"2020","unstructured":"Li X, Chen B, An C, et al. Transarterial chemoembolization combined with microwave ablation versus microwave ablation only for Barcelona Clinic Liver Cancer Stage B hepatocellular carcinoma: A propensity score matching study. J Cancer Res Ther. 2020;16(5):1027\u201337. https:\/\/doi.org\/10.4103\/jcrt.JCRT_380_19.","journal-title":"J Cancer Res Ther"},{"issue":"12","key":"1478_CR20","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/j.jvir.2019.07.029","volume":"30","author":"D Liu","year":"2019","unstructured":"Liu D, Liu M, Su L, et al. Transarterial Chemoembolization Followed by Radiofrequency Ablation for Hepatocellular Carcinoma: Impact of the Time Interval between the Two Treatments on Outcome. J Vasc Interv Radiol. 2019;30(12):1879\u201386. https:\/\/doi.org\/10.1016\/j.jvir.2019.07.029.","journal-title":"J Vasc Interv Radiol"},{"key":"1478_CR21","doi-asserted-by":"publisher","unstructured":"Huang Z-M, Han X, Wang J, et al. A prospective, single-arm, phase 2 study of modified transarterial chemoembolization using low-dose chemotherapy with blank microspheres plus low-dose lenvatinib and microwave ablation in patients with large (\u2265\u20097\u00a0cm) unresectable hepatocellular carcinoma: The TALEM Trial. Liver Cancer. 2024;1\u201313. https:\/\/doi.org\/10.1159\/000536518.","DOI":"10.1159\/000536518"},{"issue":"2","key":"1478_CR22","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3348\/kjr.2018.19.2.237","volume":"19","author":"L Zheng","year":"2018","unstructured":"ZhengL, Li HL, Guo CY, Luo SX. Comparison of the Efficacy and Prognostic Factors of Transarterial Chemoembolization Plus Microwave Ablation versus Transarterial Chemoembolization Alone in Patients with a Large Solitary or Multinodular Hepatocellular Carcinomas. Korean J Radiol. 2018;19(2):237\u201346. IF: 3.3 Q2 B3 https:\/\/doi.org\/10.3348\/kjr.2018.19.2.237","journal-title":"Korean J Radiol"},{"issue":"2","key":"1478_CR23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S2468-1253(22)00339-9","volume":"8","author":"CL Chiang","year":"2023","unstructured":"Chiang CL, Chiu KWH, Chan KSK, et al. Sequential transarterial chemoembolization and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(2):169\u201378. https:\/\/pubmed.ncbi.nlm.nih.gov\/36529152\/","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1478_CR24","doi-asserted-by":"publisher","first-page":"1354964","DOI":"10.3389\/fonc.2024.1354964","volume":"14","author":"HL Lee","year":"2024","unstructured":"Lee HL, Kim SH, Kim HY, Lee SW, Song MJ. A refined prediction model for survival in hepatocellular carcinoma patients treated with transarterial chemoembolization. Front Oncol. 2024;14:1354964. Published 2024 Mar 28. IF: 3.3 Q2 B3 https:\/\/doi.org\/10.3389\/fonc.2024.1354964","journal-title":"Front Oncol"},{"issue":"5","key":"1478_CR25","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1159\/000525500","volume":"11","author":"M Ikeda","year":"2022","unstructured":"IkedaM, Arai Y, Inaba Y, et al. Conventional or Drug-Eluting Beads? Randomized Controlled Study of Chemoembolization for Hepatocellular Carcinoma: JIVROSG-1302. Liver Cancer. 2022;11(5):440\u201350. . Published 2022 Jun 15. IF: 9.1 Q1 B1 https:\/\/doi.org\/10.1159\/000525500","journal-title":"Liver Cancer"},{"issue":"1","key":"1478_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/hep.32323","volume":"76","author":"Z Wang","year":"2022","unstructured":"Wang Z, Liu M, Zhang DZ, et al. Microwave ablation versus laparoscopic resection as first-line therapy for solitary 3\u20135 cm HCC. Hepatology. 2022;76(1):66\u201377. https:\/\/doi.org\/10.1002\/hep.32323","journal-title":"Hepatology"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01478-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01478-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01478-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T14:51:34Z","timestamp":1778338294000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01478-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1478"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01478-y","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"28 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involving human participants was reviewed and approved by the Ethics Committee of the General Hospital of the People\u2019s Liberation Army, with the ethical approval number S2019-348-01. Due to the retrospective nature of this study, the Ethics Committee waived the requirement for written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}